Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
- Bavencio® (avelumab): Non-Small Cell Lung Cancer (in collaboration w/Merck KGaA)
- Braftovi® (encorafinib) + Mektovi® (binimetinib): BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
- Duchenne Muscular Dystrophy Gene Therapy
- fidanacogene elaparvovec (Gene Therapy, coagulation factor IX): Hemophilia
- giroctocogene fitelparvovec (Gene Therapy, coagulation factor VIII): Hemophilia
- Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
- Prophylactic Vaccine: Clostridioides difficile Infection
- Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal)
- Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata
- Talzenna® (talazoparib): Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
- Xeljanz® (tofacitinib): Ankylosing Spondylitis
- Xtandi® (enzalutamide): Metastatic Castration Sensitive Prostate Cancer, Non-Metastatic High-Risk Castration Sensitive Prostate Cancer
Pipeline Snapshot as of February 2, 2021
- Discovery Projects
- 27Phase 1
- 35Phase 2
- 24Phase 3
- 9Registration
- Total95
Compound Name | Indication | Phase | Submission Type | Compound Type |
---|---|---|---|---|
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/CMP-001 for Head and Neck Cancer (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) | Phase 2 | Product Enhancement | Biologic |
Braftovi (encorafinib) + Erbitux® (cetuximab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor | 1st line BRAF-mutant Metastatic Colorectal Cancer
Project advanced | Phase 3 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor | BRAF-mutant Metastatic Melanoma Brain Metastasis (ORPHAN - U.S.) | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor | 1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer | Phase 2 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | 2nd Line Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer | Phase 2 | Product Enhancement | Small Molecule |
PF-05082566 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: CD137 Agonist | Combo w/Kite Pharma'sYescarta® (axicabtagene ciloleucel)forCancer(Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06804103 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: HER2 Antibody Drug Conjugate | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06821497 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: EZH2 Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-06863135 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: BCMA-CD3 Bispecific Antibody | Multiple Myeloma (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-06936308 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Therapeutic Vaccine | Multiple Cancers | Phase 1 | New Molecular Entity | Small Molecule |
PF-06939999 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: protein arginine methyltransferase 5 (PRMT5) Inhibitor | Solid Tumors | Phase 1 | New Molecular Entity | Small Molecule |
PF-06940434 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Integrin alpha-V/beta-8 Antagonist | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06952229 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |